IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Toshiyuki Takai, et al.

U.S. Appln. No.

10/712,118

U.S. Filing Date

November 13, 2003

Title of Invention

NON-HUMAN ANIMAL MODEL OF OLIGODENDROCYTE

DEVELOPMENTAL DISORDER

Confirm No.

8301

Examiner

:

xammer

Joanne Hama, Ph.D

Art Unit

1632

745 Fifth Avenue New York, NY 10151

FILED VIA EFS-WEB January 28, 2009

SECOND REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

It is requested that a Certificate of Correction be issued in the above-entitled patent in accordance with the accompanying form PTO 1050. Please make the following changes:

ON THE FACE OF THE PATENT

(75) Toshiyuki Takai, "Sendai" -- Miyagi-- (JP)

IN THE CLAIMS

Col. 19, claim 2, line 28

The transgenic mouse model of claim 1, wherein the homozygous disruption in the DAP12 gene can be "should read pheonotypically" --phenotypically-- exhibited as a myelinogenesis developmental disorder.

Col. 20, claim 5, lines 25 and 27

The transgenic mouse model of claim 1, "weherein" --wherein-- the expression of myelin basic protein in the brain is weak in regions where DAP "space" 12 is strongly expressed in wild-type mice.

REMARKS

The requested changes do not constitute new matter and this application does not require re-examination. A completed Form PTO 1050 is enclosed. In the correction to claim 5, line 27, Applicant is requesting that the Office delete the space between "DAP" and "12." Therefore, the compound should read as "DAP12" as written on the attached Certificate of Correction

The errors to be corrected in this second Request are the Patent Office errors and not the Applicants' errors, therefore, no fee is deemed necessary. The Commissioner is also authorized to charge any additional fees or credit any overpayments to Deposit Account No. 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By:

Thomas J. Kowalski

Reg. No. 32,147

Russell A. Garman Reg. No. 62,419

Telephone: (212) 588-0800 Facsimile: (212) 588-0500

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO.

7,332,644

APPLICATION NO.

10/712,118

ISSUE DATE

February 19, 2008

INVENTOR(S)

Toshiyuki Takai

Hiroaki Aso

Michihiro Fujiwara

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

ON THE FACE OF THE PATENT

(75)

Toshiyuki Takai, Miyagi (JP)

IN THE CLAIMS

Col. 19, claim 2, line 28

The transgenic mouse model of claim 1, wherein the homozygous disruption in the DAP12 gene can be phenotypically exhibited as a myelinogenesis developmental disorder.

Col. 20, claim 5, line 25 and 27

The transgenic mouse model of claim 1, wherein the expression of myelin basic protein in the brain is weak in regions where DAP12 is strongly expressed in wild-type mice.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Thomas J. Kowalski, Esq. Frommer Lawrence & Haug LLP 745 Fifth Avenue New York, New York 10151

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.